France will start reimbursing the cost of weight‑loss medications prescribed to severely obese patients from mid‑June, becoming the first EU member to implement such a policy.
The reimbursement applies to Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, which patients currently pay roughly €300 per month for.
Health Minister Stéphanie Rist estimates the programme’s annual budgetary impact at about €100 million (≈ $116 million) at full rollout, targeting roughly one million eligible individuals, though actual uptake will depend on case‑by‑case medical assessment and physician prescription.
